Valeur2022202320242025TTMFrais de vente, généraux et administratifs73.36 M70.45 M61.51 M61.51 M59.6 MRecherche et développement208.6 M143.62 M151.91 M137 M135.72 MRésultat d'exploitation130.53 M-138.05 M-137.11 M-92.55 M-114.05 MTotal des produits hors exploitation1.11 M-894 K558 K-559 K-488 KCharges d'intérêts, nettes des intérêts capitalisés—————Résultat hors exploitation, hors charges d'intérêts1.15 M-1.19 M776 K-610 K-514 KRevenus/dépenses exceptionnels-42 K291 K-218 K51 K—Résultat avant impôts135.23 M-119.24 M-116.61 M-79.75 M-103.97 MPart des actionnaires dans le résultat—————Impôts10.89 M-568 K6.08 M1.38 M-1.31 MIntérêts ne donnant pas le contrôle / intérêts minoritaires—————Autres produits/charges après impôts—————Résultat net avant activités abandonnées124.34 M-118.67 M-122.69 M-81.13 M-102.66 MActivités abandonnées—————Résultat net124.34 M-118.67 M-122.69 M-81.13 M-102.66 MAjustement de dilution—————Dividendes privilégiés—————Résultat net dilué revenant aux actionnaires ordinaires124.11 M-118.67 M-122.56 M-81.33 M-102.73 MBénéfice par action de base (BPA de base)1.91-1.72-1.62-1.08-1.37Bénéfice par action dilué (BPA dilué)1.9-1.72-1.62-1.08-1.37Nombre moyen d'actions de base en circulation65.19 M68.86 M75.85 M75.4 M—Nombre d'actions en circulation après dilution65.25 M68.86 M75.88 M75.41 M—EBITDA137.76 M-127.89 M-128.43 M-84.82 M-98.28 MEBIT130.53 M-138.05 M-137.11 M-92.55 M-114.05 MCoût des ventes—————Autres coûts des ventes—————Amortissements (flux de trésorerie)7.24 M10.16 M8.68 M7.72 M15.77 M
Zymeworks Inc. - Common Stock
Zymeworks Inc. is a publicly held biotechnology company based in Vancouver,
British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange.
In May 2019, Zymeworks announced that GSK has expanded its 2016 licensing and collaboration agreement for the research, development and commercialization of bispecific antibodies across multiple disease areas. The extended agreement has meant that GSK can have access to Zymeworks' heavy-light chain pairing technology, which enables the development of bispecific and multifunctional therapeutics.